KIF7 attenuates prostate tumor growth through LKB1-mediated AKT inhibition

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• Prostate cancer (PCa) remains a significant health concern with ongoing research into its molecular drivers.
• Understanding the role of specific genes, such as kinesin family member 7 (KIF7), is crucial for developing targeted therapies.

Purpose of the Study:

• To investigate the expression and functional role of KIF7 in prostate cancer.
• To elucidate the specific domains of KIF7 involved in PCa regulation and the underlying molecular mechanisms.

Main Methods:

• Analysis of KIF7 expression in PCa tissues versus normal and pre-cancerous tissues.
• In vitro and in vivo studies using KIF7 coiled-coil (CC) and motor (MD) domains in PCa models.
• Investigation of the KIF7-LKB1-PTEN-AKT signaling pathway.

Main Results:

• KIF7 expression is significantly downregulated in PCa, partly due to promoter hypermethylation.
• KIF7-CC domain, but not KIF7-MD, suppressed PCa cell proliferation, colony formation, migration, and invasion.
• KIF7-CC induced apoptosis, sensitized PCa cells to paclitaxel, and inhibited tumor growth in xenografts.
• KIF7-CC functions through enhancing LKB1 expression and activity, leading to PTEN activation and subsequent inhibition of AKT phosphorylation.

Conclusions:

• KIF7 acts as a tumor suppressor in prostate cancer.
• The KIF7-CC domain inhibits PCa development via the LKB1-mediated suppression of the AKT pathway.
• KIF7 represents a potential therapeutic target for prostate cancer treatment.